8-K filing — CUMBERLAND PHARMACEUTICALS INC (CPIX)
Filed: 2026-08-04 AccNo: 0001087294-26-000058 Size: 437 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data
Cumberland Pharma shares rose after Phase 2 data showed ifetroban improved heart function in Duchenne muscular dystrophy patients.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 26, 2026, 5:53 PM
- Checked
- Jun 26, 2026, 5:55 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cumberland Q2 Adj. EPS $(0.20) Down From $(0.13) YoY, Sales $166.458K Down From $380.797K YoY
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.20) per share. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $166.458 thousand in sales
Read original at benzingaCumberland Pharmaceuticals Declares $1.50/Share Special Dividend
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special
Read original at benzinga